Drug intelligence / Profile preview

norepinephrine

Development stage
Approved
Lead developer
Pfizer
Modality
Small Molecules
Administration
Intravenous
01

Overview

Norepinephrine (also known as noradrenaline or 去甲肾上腺素) is a potent vasopressor and catecholamine used primarily to treat life-threatening hypotension (low blood pressure), especially in cases of septic shock and other acute hypotensive states. It acts mainly by stimulating alpha-adrenergic receptors on vascular smooth muscle to cause vasoconstriction and increase peripheral vascular resistance, leading to elevated blood pressure. Norepinephrine also has some beta-1 adrenergic activity that can enhance cardiac contractility but has minimal effect on beta-2 receptors. It is administered intravenously due to poor oral bioavailability and rapid metabolism if taken orally. The drug was first developed in 1946 and approved for medical use in the United States in 1950[1][2][7]. Common side effects include headache, bradycardia (slow heart rate), anxiety, arrhythmias, tissue necrosis at the injection site if extravasation occurs[1][6][7].

Brand names
LevophedLevarterenol
Other names
去甲肾上腺素noradrenaline正肾上腺素levonorepinephrine
02

Targets

ADRA1A (α1A)ADRB1 (β1)ADRA2A (α2A)

Beyond the preview

Go deeper on norepinephrine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on norepinephrine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call